ADC Therapeutics (ADCT) Retained Earnings (2019 - 2026)

ADC Therapeutics (ADCT) has reported Retained Earnings for 8 consecutive years, with -$1.7 billion the latest figure, recorded in Q1 2026.

• Quarterly Retained Earnings fell 8.94% year-over-year to -$1.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.7 billion (down 8.94% YoY) and the FY2025 annual result came in at -$1.6 billion, down 9.55% from the prior year.
• Retained Earnings eased to -$1.7 billion in Q1 2026 per ADCT's latest filing, from -$1.6 billion in the prior quarter.
• Over the last five years, Retained Earnings for ADCT reached as high as $1.2 billion in Q4 2022 and fell as low as -$1.7 billion in Q1 2026.
• A 5-year average of -$1.2 billion and a median of -$1.4 billion in 2024 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2022 — Retained Earnings surged 226.11% — and 2023, when it tumbled 214.49%.
• Year by year, Retained Earnings stood at $1.2 billion in 2022, then slumped by 214.49% to -$1.3 billion in 2023, then fell by 11.82% to -$1.5 billion in 2024, then decreased by 9.55% to -$1.6 billion in 2025, then slipped by 2.02% to -$1.7 billion in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$1.7 billion, -$1.6 billion, and -$1.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.